Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Status Terminated

Clinical Trial Summary

This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Clinical Trial Description

OUTLINE: Patients receive olaparib orally (PO) twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up to 1 year. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04951492
Study type	Interventional
Source	University of Washington
Contact
Status	Terminated
Phase	Phase 2
Start date	November 9, 2022
Completion date	October 15, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03796767` - Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer	Phase 2
Completed	`NCT04400656` - PROState Pathway Embedded Comparative Trial
Completed	`NCT05735223` - A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence	N/A
Recruiting	`NCT04175431` - Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study	Phase 2
Completed	`NCT05197257` - 68Ga-PSMA-11 PET in Patients With Prostate Cancer	Phase 3
Withdrawn	`NCT03982173` - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors	Phase 2
Terminated	`NCT02491411` - Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel	N/A
Active, not recruiting	`NCT02254746` - A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer	N/A
Active, not recruiting	`NCT05496959` - 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study	Phase 2
Completed	`NCT02940262` - Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy	Phase 3
Recruiting	`NCT04391556` - Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma	Phase 2
Enrolling by invitation	`NCT03503643` - Hemi-Gland Cryoablation for Prostate Cancer at UCLA
Recruiting	`NCT05832086` - Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes	Phase 2
Suspended	`NCT05064111` - Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy
Not yet recruiting	`NCT04031378` - Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer	Phase 2
Recruiting	`NCT02600156` - Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors	N/A
Recruiting	`NCT05726292` - A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer	Phase 2
Recruiting	`NCT04423211` - Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging	Phase 3
Terminated	`NCT03718338` - Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
Terminated	`NCT02564549` - MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca	N/A